Table 1 Cohort and Subgroup Characteristics.

From: Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma

 

Cohort

HCV Patients

Non-DAA Patients

DAA Patients

Non-SVR12 Patients

SVR12 Patients

Age at HCC Diagnosis (years) (mean ± stdev)

62.8 ± 10.2

60.5 ± 7.7

59.9 ± 7.7

61.7 ± 5.8

61.6 ± 5.3

61.8 ± 6.1

Sex

Male

768 (79.3%)

390 (83.0%)

202 (82.4%)

99 (80.5%)

28 (90.3%)

63 (75.9%)

Female

201 (20.7%)

80 (17.0%)

43 (17.6%)

24 (19.5%)

3 (9.7%)

20 (24.1%)

Liver Factors

AJCC

   1

400 (43.8%)

198 (44.5%)

79 (34.5%)

79 (65.3%)

15 (48.4%)

58 (71.6%)

   2

244 (26.7%)

110 (24.7%)

63 (27.5%)

31 (25.6%)

11 (35.5%)

19 (23.5%)

   3

162 (17.7%)

86 (19.3%)

53 (23.1%)

8 (6.6%)

3 (9.7%)

4 (4.9%)

   4

107 (11.7%)

51 (11.5%)

34 (14.8%)

3 (2.5%)

2 (6.5%)

0

Child Pugh Score

   A

512 (55.2%)

254 (56.3%)

116 (49.2%)

84 (68.9%)

24 (77.4%)

54 (65.9%)

   B

284 (30.6%)

132 (29.3%)

80 (33.9%)

30 (24.6%)

6 (19.4%)

21 (25.6%)

   C

132 (14.2%)

65 (14.4%)

40 (16.9%)

8 (6.6%)

1 (3.2%)

7 (8.5%)

MELD (mean ± stdev)

11.4 ± 5.7

10.7 ± 4.6

11.4 ± 5.2

9.5 ± 3.4

9.3 ± 3.1

9.67 ± 3.5

Tumor Size (cm) (mean ± stdev)

4.48 ± 3.6

4.18 ± 3.3

4.70 ± 3.6

2.76 ± 1.7

3.09 ± 2.4

2.57 ± 1.3

Tumor Location

   Unilobar

628 (66.7%)

298 (65.1%)

137 (57.6%)

93 (75.6%)

17 (54.8%)

68 (81.9%)

   Bilobar

314 (33.3%)

160 (34.9%)

101 (42.4%)

30 (24.4%)

14 (45.2%)

15 (18.1%)

Multiple Tumors

   yes

442 (45.9%)

225 (48.4%)

133 (55.0%)

47 (38.2%)

19 (61.3%)

27 (32.5%)

   no

520 (54.1%)

240 (51.6%)

109 (45.0%)

76 (61.8%)

12 (38.7%)

56 (67.5%)

Main Treatment

Transplant

125 (13.2%)

0

0

0

0

0

Resection

112 (11.8%)

56 (12.1%)

21 (8.6%)

21 (17.4%)

5 (16.1%)

16 (19.5%)

IO

478 (50.3%)

285 (61.6%)

143 (58.4%)

93 (76.9%)

24 (77.4%)

63 (76.8%)

Systemic

94 (9.9%)

45 (9.7%)

26 (10.6%)

4 (3.3%)

1 (3.2%)

1 (1.2%)

Supportive

141 (14.8%)

77 (16.6%)

55 (22.4%)

3 (2.5%)

1 (3.2%)

2 (2.4%)

Hepatitis C Factors

HCV Infection

551 (56.9%)

470

245

123

31

83

DAA Treatment

 

123 (26.2%)

0

123

31

83

SVR12

   

83 (67.5%)

0

83

  1. Characteristics of cohort, HCV, non-DAA, DAA, non-SVR12 and SVR12 subgroups, n (%) or mean ± standard deviation as marked. AJCC: American Joint Committee on Cancer stage, MELD: model for end stage liver disease, IO: interventional oncology, HCV: hepatitis C, DAA: direct-acting antivirals, SVR12: sustained viral response at 12 weeks.
Back to article page